NGENF NervGen Pharma Corp.

NervGen Pharma Corp., a biotech company, discovers and develops treatments for patients suffering from medical conditions related to nerve damage. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Note: This is not a U.S. company, but they cross-list their shares on the U.S. over-the-counter market - see the related symbol CV:NGEN.

$2.13    OTCQX
As of 01/14/2022     OTCMarkets

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  
IPO date:  04/03/2019
Outstanding shares:  46,189,584
Average volume:  30,836
Market cap:   $97,460,022
Current dividend yield:  0.00%
Sedol:      

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   10.54
PS ratio:   0.00
Return on equity:   -158.58%
Net income %:   0.00%